

Supplementary Table 1. Patient demographics [p reflect comparison to No Medication (NO MED)] group.

	NO MED n = 38 (%)	MED n = 34 (%)	Matched Controls n = 114 (%)	Unmatched Controls n = 114 (%)
Age at diagnosis (yrs)	36.1 ± 15.2	27.9 ± 11.7 <i>p</i> = 0.01	36.6 ± 14.9 <i>p</i> = 0.87	29.7 ± 14.6 <i>p</i> = 0.02
Age at first visit (yrs)	38.5 ± 15.0	33.8 ± 11.6 <i>p</i> = 0.14	38.7 ± 14.5 <i>p</i> = 0.97	33.4 ± 13.9 <i>p</i> = 0.05
Sex (F)	32 (84.2)	33 (97.1) <i>p</i> = 0.11	96 (84.2) <i>p</i> = 1.00	106 (93.0) <i>p</i> = 0.12
Race*				
White	32 (84)	25 (74)	82 (72)	83 (73)
Black	0 (0)	4 (12)	16 (14)	10 (9)
Asian	2 (5)	4 (12)	10 (9)	10 (9)
Other	4 (11)	1 (3) <i>p</i> = 0.27	6 (5) <i>p</i> = 0.02	11 (10) <i>p</i> = 0.16
Disease duration at first visit (yrs)	2.4 ± 5.8	5.9 ± 7.0 <i>p</i> = 0.02	2.1 ± 4.5 <i>p</i> = 0.71	3.7 ± 6.0 <i>p</i> = 0.23
Duration of clinic followup (yrs)	23.8 ± 10.6	24.0 ± 10.4 <i>p</i> = 0.94	19.1 ± 9.1 <i>p</i> = 0.009	16.0 ± 8.0 <i>p</i> = 0.0001

* White vs all others.

Supplementary Table 2. Clinical and laboratory characteristics at visit 2 years from clinic entry [if prior to remission; p reflect comparison to No Medication (NO MED) group].

	NO MED n = 28 (%)	MED n = 21 (%)	p	Matched Controls n = 88 (%)	p	Unmatched Controls n = 103 (%)	p
SLEDAI-2K (score)	3.4 ± 3.2	5.4 ± 4.7	0.07	5.8 ± 5.3	0.005	5.7 ± 5.0	0.004
Corticosteroid (% use)	60.7	95.2	0.007	81.8	0.02	79.6	0.04
Antimalarial (% use)	35.7	33.3	0.86	50.0	0.19	57.3	0.04
Immunosuppressive (% use)	32.1	42.9	0.44	35.2	0.76	42.7	0.31
Musculoskeletal	28.6	23.8	0.71	27.3	0.89	26.2	0.80
Skin	82.1	81.0	1.00	88.6	0.35	89.3	0.33
Vasculitis	17.9	19.1	1.00	26.1	0.37	24.3	0.47
Renal	46.4	47.6	0.93	61.4	0.16	67.0	0.05
Central nervous system	25.0	42.9	0.19	40.9	0.13	38.8	0.18
Cardiac – SLE-related	17.9	14.3	1.00	26.1	0.37	22.3	0.61
Cardiac – atherosclerotic	10.7	4.8	0.63	3.4	0.15	2.9	0.11
Thrombotic	6.7	12.5	1.00	7.3	1.00	14.6	0.67
Pulmonary	0	19.1	0.03	19.3	0.01	23.3	0.005
Leukopenia	14.3	0	0.12	10.2	0.51	10.7	0.74
Thrombocytopenia	25.0	14.3	0.48	11.4	0.12	14.6	0.25
Coombs	39.3	38.1	0.93	37.5	0.87	36.9	0.82
Anti-Jo1	7.1	9.5	1.00	3.4	0.59	1.9	0.20
Anti-La	21.4	14.3	0.71	10.2	0.19	6.8	0.03
Anti-RNP	10.7	14.3	1.00	14.8	0.76	22.3	0.17
Anti-Ro	28.6	23.8	0.71	21.6	0.45	17.5	0.19
Anti-SCL70	17.9	9.5	0.68	6.8	0.13	5.8	0.06
Anti-Smith	14.3	9.5	0.69	10.2	0.51	14.6	1.00
ANCA	0	0	N/A	1.1	1.00	1.9	1.00
Anti-dsDNA (Farr)	42.9	52.4	0.51	64.8	0.04	64.1	0.04
ANA	92.9	95.2	1.00	95.5	0.63	97.1	0.29

SLE: systemic lupus erythematosus; Anti-Jo1: antibody not Jo-1; SCL: Symptom Checklist; ANCA: antineutrophil cytoplasmic antibodies; ANA: antinuclear antibody.

Supplementary Table 3. Clinical and laboratory characteristics at visit 5 years from clinic entry [if prior to remission; p reflect comparison to No Medication (NO MED) group].

	NO MED n = 20 (%)	MED n = 15 (%)	p	Matched Controls n = 59 (%)	p	Unmatched Controls n = 104 (%)	p
SLEDAI-2K (score)	3.1 ± 4.2	4.1 ± 4.6	0.47	5.1 ± 3.7	0.04	4.5 ± 4.2	0.15
Corticosteroid (% use)	60.0	100	0.006	91.5	0.003	85.6	0.01
Antimalarial (% use)	45.0	40.0	0.77	54.2	0.47	74.0	0.01
Immunosuppressive (% use)	35.0	60.0	0.14	39.0	0.75	54.8	0.10
Musculoskeletal	35.0	26.7	0.72	28.8	0.60	37.5	0.83
Skin	85.0	100	0.24	91.5	0.41	92.3	0.38
Vasculitis	40.0	20.0	0.28	39.0	0.94	29.8	0.37
Renal	45.0	73.3	0.09	80.0	0.003	77.9	0.003
Central nervous system	35.0	60.0	0.14	62.7	0.03	51.0	0.19
Cardiac – SLE-related	35.0	20.0	0.46	32.2	0.82	29.8	0.64
Cardiac – atherosclerotic	5.0	20.0	0.29	11.9	0.67	6.7	1.00
Thrombotic	8.3	0	1.00	16.1	0.66	17.9	0.68
Pulmonary	10.0	33.3	0.11	25.4	0.21	28.9	0.08
Leukopenia	25.0	0	0.06	13.6	0.30	11.5	0.15
Thrombocytopenia	30.0	13.3	0.42	17.0	0.22	24.0	0.57
Coombs	50.0	40.0	0.56	47.5	0.84	53.9	0.75
Anti-Jo1	10.0	6.7	1.00	6.8	0.64	9.6	1.00
Anti-La	20.0	13.3	0.68	17.0	0.74	15.4	0.74
Anti-RNP	25.0	20.0	1.00	17.0	0.51	30.8	0.61
Anti-Ro	25.0	20.0	1.00	27.1	0.85	26.9	0.86
Anti-SCL70	30.0	6.7	0.20	10.2	0.06	14.4	0.11
Anti-Smith	20.0	13.3	0.68	15.3	0.73	20.2	1.00
ANCA	10.0	0	0.50	6.8	0.64	12.5	1.00
Anti-dsDNA (Farr)	65.0	86.7	0.24	83.1	0.12	79.8	0.15
ANA	95.0	93.3	1.00	96.6	1.00	100	0.16

SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SLE: systemic lupus erythematosus; Anti-Jo1: antibody not Jo-1; SCL: Symptom Checklist; ANCA: antineutrophil cytoplasmic antibodies; ANA: antinuclear antibody.

Supplementary Table 4. Clinical and laboratory characteristics at visit 2 years from SLE diagnosis [if prior to remission; p reflect comparison to No Medication (NO MED) group].

	NO MED n = 23 (%)	MED n = 14 (%)	p	Matched Controls n = 76 (%)	p	Unmatched Controls n = 66 (%)	p
SLEDAI-2K (score)	3.0 ± 3.1	6.0 ± 5.0	0.06	5.4 ± 5.2	0.008	6.2 ± 5.4	0.001
Corticosteroid (% use)	56.6	100	0.006	79.0	0.03	71.2	0.20
Antimalarial (% use)	47.8	35.7	0.47	48.7	0.94	57.6	0.42
Immunosuppressive (% use)	26.1	28.6	1.00	27.6	0.88	30.3	0.70
Musculoskeletal	34.8	28.6	1.00	26.3	0.43	24.2	0.33
Skin	87.0	71.4	0.39	84.2	1.00	86.4	1.00
Vasculitis	8.7	21.4	0.35	26.3	0.07	21.2	0.22
Renal	52.2	42.9	0.58	54.0	0.88	57.6	0.65
Central nervous system	26.1	42.9	0.47	35.5	0.40	34.9	0.44
Cardiac – SLE-related	13.0	14.3	1.00	23.7	0.39	24.2	0.38
Cardiac – atherosclerotic	13.0	7.1	1.00	5.3	0.35	3.0	0.11
Thrombotic	9.1	20.0	1.00	8.6	1.00	9.4	1.00
Pulmonary	0	28.6	0.02	15.8	0.06	24.2	0.009
Leukopenia	13.0	7.1	1.00	7.9	0.43	9.1	0.69
Thrombocytopenia	17.4	21.4	1.00	9.2	0.28	12.1	0.50
Coombs	34.8	50.0	0.36	32.9	0.87	42.4	0.52
Anti-Jo1	4.4	14.3	0.54	4.0	1.00	1.5	0.45
Anti-La	21.7	21.4	1.00	9.2	0.14	7.6	0.12
Anti-RNP	8.7	14.3	0.62	15.8	0.51	27.3	0.07
Anti-Ro	34.8	35.7	1.00	26.3	0.43	15.2	0.07
Anti-SCL70	8.7	14.3	0.62	6.6	0.66	4.6	0.60
Anti-Smith	8.7	21.4	0.35	7.9	1.00	15.2	0.72
ANCA	0	0	N/A	1.3	1.00	4.6	0.57
Anti-dsDNA (Farr)	43.5	50.0	0.70	65.8	0.06	57.6	0.24
ANA	95.7	85.7	0.54	89.5	0.68	93.9	1.00

SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SLE: systemic lupus erythematosus; Anti-Jo1: antibody not Jo-1; SCL: Symptom Checklist; ANCA: antineutrophil cytoplasmic antibodies; ANA: antinuclear antibody.

Supplementary Table 5. Clinical and laboratory characteristics at visit 5 years from SLE diagnosis [if prior to remission; p reflect comparison to No Medication (NO MED) group].

	NO MED n = 15 (%)	MED n = 13 (%)	p	Matched Controls n = 53 (%)	p	Unmatched Controls n = 84 (%)	p
SLEDAI-2K (score)	3.8 ± 4.8	4.2 ± 4.7	0.85	5.9 ± 5.5	0.18	5.0 ± 5.0	0.40
Corticosteroid (% use)	53.3	100	0.007	86.8	0.009	78.6	0.05
Antimalarial (% use)	40.0	33.8	0.71	52.8	0.38	72.6	0.02
Immunosuppressive (% use)	33.3	53.9	0.27	35.9	0.86	41.7	0.54
Musculoskeletal	26.7	15.4	0.65	28.3	1.00	34.5	0.55
Skin	86.7	92.3	1.00	90.6	0.64	95.2	0.22
Vasculitis	33.3	23.3	0.69	35.9	0.86	27.4	0.76
Renal	46.7	69.2	0.23	67.9	0.13	65.5	0.17
Central nervous system	46.7	46.2	0.98	52.8	0.67	23.6	0.99
Cardiac – SLE-related	33.3	23.1	0.69	28.3	0.75	27.4	0.76
Cardiac – atherosclerotic	6.7	15.4	0.58	11.3	1.00	1.2	0.28
Thrombotic	0	0	N/A	13.0	0.55	15.4	0.58
Pulmonary	6.7	38.5	0.07	26.4	0.16	27.4	0.11
Leukopenia	20.0	0	0.23	15.1	0.70	11.9	0.41
Thrombocytopenia	33.3	15.4	0.40	18.9	0.29	22.6	0.51
Coombs	33.3	46.2	0.49	47.2	0.34	50.0	0.27
Anti-Jo1	13.3	7.7	1.00	5.7	0.30	6.0	0.29
Anti-La	20.0	15.4	1.00	13.2	0.68	10.7	0.39
Anti-RNP	20.0	15.4	1.00	18.9	1.00	33.3	0.38
Anti-Ro	33.3	23.1	0.69	26.4	0.75	20.2	0.31
Anti-SCL70	20.0	7.7	0.60	7.6	0.18	11.9	0.41
Anti-Smith	20.0	23.1	1.00	13.2	0.68	20.2	1.00
ANCA	13.3	0	0.48	5.7	0.30	8.3	0.62
Anti-dsDNA (Farr)	66.7	69.2	1.00	75.5	0.52	67.9	1.00
ANA	93.3	92.3	1.00	90.6	1.00	98.8	0.28

SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SLE: systemic lupus erythematosus; Anti-Jo1: antibody not Jo-1; SCL: Symptom Checklist; ANCA: antineutrophil cytoplasmic antibodies; ANA: antinuclear antibody.